Within every cell, a small enzyme must strike a delicate balance, consuming the amino acid tryptophan just enough to keep the body's chemistry running without draining a nutrient it cannot manufacture on its own. Researchers working across Germany, Nevada and Belgium have now found that tryptophan itself guards the enzyme that consumes it, sheltering a hidden tag that would otherwise mark the protein for destruction. It is a quiet reminder that the things we are made from can also be the signals that tell our machinery when to hold on and when to let go.
How Tryptophan Shields the Enzyme That Consumes It From Degradation
Tryptophan is also a signal that decides how long its own consumer survives
Mark
So what's the core finding here?
Mimi
Tryptophan does two jobs on TDO2. It's the thing the enzyme breaks down, and it also sits in a separate second site where it folds a flap over a degradation signal.
Mark
And when tryptophan runs low?
Mimi
It leaves that site, the flap loosens, CK2 adds phosphate groups, CUL1–β-TrCP adds ubiquitin, and the proteasome clears the enzyme.
Luke
Worth saying what was already known. The feedback itself dates to the 1950s, and the second binding site was known too. The new part is the mechanism linking them.
Mark
How did they establish it?
Mimi
A genome-wide CRISPRi screen found CK2 and CUL1–β-TrCP, then test-tube reactions with purified proteins and cryo-electron microscopy showed the flap with and without tryptophan.
Luke
Those are structural and biochemical results. The source doesn't describe any drug testing, so the therapeutic angle is a possibility, not a result.
Mark
Why does the drug point matter, then?
Mimi
Schulman notes that a drug aimed at the active site might also bind the second site and accidentally stabilize TDO2. A molecule that fills the second site but leaves the signal exposed could do the opposite.
Luke
Both of those are stated as could-happen scenarios. And the claim that this is a general principle across metabolism is something the group says it is now investigating, not something shown.
O Pulso
- Tryptophan is being consumed by TDO2 faster than the body can replace it, creating a tightening squeeze on a nutrient the cell cannot make.
- When tryptophan runs low, a kinase called CK2 tags TDO2 like a marker on a shipping crate, and the cellular disposal system is primed to act.
- Researchers mapped the hidden switch with cryo-electron microscopy, revealing a protein flap that folds over a second binding site to conceal the destruction signal.
- The discovery opens a path toward drugs that could target this regulatory site, a move that could help in neurological disorders and cancers where TDO2 runs too high.
Within every cell, a small enzyme must strike a delicate balance, consuming the amino acid tryptophan just enough to keep the body's chemistry running without draining a nutrient it cannot manufacture on its own. Researchers working across Germany, Nevada and Belgium have now found that tryptophan itself guards the enzyme that consumes it, sheltering a hidden tag that would otherwise mark the protein for destruction. It is a quiet reminder that the things we are made from can also be the signals that tell our machinery when to hold on and when to let go.
Inside a cell, an enzyme called TDO2 performs the first and most consequential step in breaking down tryptophan. Too little activity leaves the cell short of downstream products; too much drains a nutrient the body can only obtain from food. A team at the Max Planck Institute of Biochemistry, working with colleagues at the University of Nevada, Las Vegas, and the de Duve Institute in Brussels, has now shown how the cell keeps this balance, and the answer is striking: tryptophan protects the enzyme that consumes it.
Tryptophan matters far beyond its role as a protein building block. It is the precursor to serotonin, melatonin, niacin and NAD+, molecules that sustain the nervous system, the immune system and the cell's energy supply. Since the body cannot make it, levels must be held within a narrow range. Scientists have known since the 1950s that TDO2 remains stable when tryptophan is abundant and collapses when supply falls, and later work tied this to the ubiquitin-proteasome system. What was missing was the mechanism by which tryptophan controlled that machinery.
First author Alina Thielen and her colleagues used a genome-wide CRISPRi screen to find the proteins driving TDO2 degradation, which pointed to the kinase CK2 and the E3 ligase CUL1–β-TrCP. In sequence, CK2 phosphorylates TDO2 when tryptophan is scarce, and CUL1–β-TrCP attaches ubiquitin, marking the enzyme for the proteasome. Cryo-electron microscopy then revealed the crucial detail. Tryptophan bound to a second site, away from the catalytic center, organizes a nearby section of the protein into a flap that folds over the recognition sequence, hiding it. When tryptophan departs, the flap loosens, the sequence is exposed, and degradation begins.
The implications reach into medicine. TDO2 is elevated in neurological disorders and in many cancers, where excess activity can blunt the antitumor immune response, making it an attractive drug target. Brenda Schulman warns, however, that a drug aimed at the consumption site might inadvertently bind the second site and stabilize the enzyme. A molecule that occupies the second site while leaving the degradation signal exposed could do the opposite. The group now asks whether cells use this same logic, letting a metabolite govern the lifespan of the enzyme it feeds on, to tune metabolism more broadly to nutrient supply.
Inside a cell, an enzyme called TDO2 does a job that has to be done carefully. It performs the first, rate-limiting step of the kynurenine pathway, breaking down the amino acid tryptophan. Too little activity and the cell is short of downstream products. Too much and it drains a nutrient the body can only get from food. A team at the Max Planck Institute of Biochemistry has now shown how the cell manages that balance, and the answer is that tryptophan protects the very enzyme that consumes it.
The work, done with colleagues at the University of Nevada, Las Vegas, and the de Duve Institute in Brussels, appears in Molecular Cell. The background matters here. Tryptophan is a building block for proteins and a precursor for serotonin, melatonin, niacin (vitamin B3) and NAD+, molecules that support the nervous and immune systems and the cell's energy supply. Because the body cannot make tryptophan, it has to keep levels within a physiological range.
Researchers have known since the 1950s that TDO2 is stable when tryptophan is plentiful and is rapidly broken down when supply runs short. More recently it was shown that this feedback depends on the ubiquitin-proteasome system, the machinery that marks unwanted proteins and degrades them. What remained unexplained was how tryptophan controls that system.
To find out, first author Alina Thielen and colleagues ran a genome-wide CRISPRi screen to identify the proteins driving TDO2 degradation. It pointed to two: the kinase CK2 and the E3 ligase CUL1–β-TrCP. The team then reconstituted the reactions with purified proteins in a test tube. They also used cryo-electron microscopy to image TDO2 with and without tryptophan sitting in a second binding site.
The two proteins work in sequence. When tryptophan is scarce, CK2 attaches phosphate groups to TDO2. That phosphorylation acts as a recognition signal for CUL1–β-TrCP, which then attaches ubiquitin. The proteasome, the cell's waste disposal system, recognizes the ubiquitin-tagged enzyme and degrades it.
The second binding site was already known. It lies away from the catalytic center, where tryptophan is actually consumed. What the microscopy revealed, Thielen explains, is that tryptophan organizes a section of the protein near that site. This section folds over the bound tryptophan like a flap, so the nearby recognition sequence for CK2 and CUL1–β-TrCP is inaccessible. When tryptophan levels fall, the amino acid leaves the second site, the flap becomes unstructured, and the sequence is exposed. That starts degradation.
The finding has therapeutic implications. TDO2 is upregulated in neurological disorders and in various cancers, and in tumors, high levels can weaken the antitumor immune response, which makes the enzyme a potential drug target. Brenda Schulman cautions that a drug aimed at the site where the enzyme consumes tryptophan could also bind the second site and unintentionally stabilize TDO2. Conversely, a molecule that occupies the second site while leaving the CK2 and CUL1–β-TrCP recognition sequence accessible could induce TDO2 degradation.
Schulman describes the broader point: tryptophan is not only a substrate but also a signal that determines how long TDO2 persists in the cell, an example of a metabolite directly controlling the stability of the enzyme that consumes it. The group is now investigating whether cells use this strategy more widely to tune metabolism to nutrient supply.
Citações Notáveis
Tryptophan is not only a metabolite and substrate for TDO2; it also acts as a signal that determines how long the enzyme remains stable within the cell.— Brenda Schulman, Max Planck Institute of Biochemistry
The section folds over the bound tryptophan like a flap, making the nearby recognition sequence for CK2 and CUL1–β-TrCP inaccessible.— Alina Thielen, first author
Quer a matéria completa?
Leia o original em Phys.org ↗
Education